Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20 2024 - 4:05PM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing novel targeted therapies for
RAS-addicted cancers, today announced that it will report financial
results for the fourth quarter and full year 2023 on Monday,
February 26, 2024, after market close. At 4:30 p.m. Eastern Time
that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior
management team will host a webcast to discuss the financial
results for the quarter and full year, and provide an update on
corporate progress.
To listen to the live webcast, or access the
archived webcast, please visit:
https://ir.revmed.com/events-and-presentations. Following the live
webcast, a replay will be available on the company’s website for at
least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage
oncology company developing novel targeted therapies for
RAS-addicted cancers. The company’s R&D pipeline comprises
RAS(ON) inhibitors designed to suppress diverse oncogenic variants
of RAS proteins, and RAS companion inhibitors for use in
combination treatment strategies. The company’s RAS(ON) inhibitors
RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON)
G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective
inhibitor, are currently in clinical development. Additional
RAS(ON) mutant-selective inhibitors in the company’s development
pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839
(G13C).
Revolution Medicines Media & Investor Contact:
Erin Graves
650-779-0136
egraves@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart
From Aug 2023 to Aug 2024